Alkion and the EIC Accelerator: Vaccine Adjuvant Without the Tree

QS-21 is a vaccine adjuvant, an ingredient that strengthens the immune response, extracted from the bark of the Chilean soapbark tree, Quillaja saponaria. Alkion BioInnovations, a French company founded in 2017, grows the tree's tissue in bioreactors, which it says produces the raw material in six weeks rather than the seven years a tree needs.

The European Innovation Council granted €2,500,000 towards AlkaBurst2.0, a €3.59 million project that ran from November 2022 to July 2025. According to the CORDIS report, it designed and validated a 40-litre modular bioreactor and produced purified QS-21 whose analysis "confirmed equivalence with pharmaceutical-grade reference materials". In November 2025 Alkion raised €4.4 million, led by GO Capital and Critical Path Ventures, to scale up to production under pharmaceutical manufacturing rules (GMP).

Where Alkion Stands Today

The November 2025 round funds "GMP-scale production of strategic adjuvants", in chief executive Sarah-Meryll Buet's words, using larger temporary immersion bioreactors and AI-assisted robotics. GO Capital's investment director Alexandre Boulay presented it as "reinforcing European health sovereignty". The announcement named no customer. The French register shows no insolvency proceedings and 13 employees in 2025.

The Technology: Growing Bark Without the Tree

The report describes a production workflow for Quillaja biomass: plant tissue multiplied in temporary immersion bioreactors, then extracted and purified into QS-21 and other saponin fractions. The design scales "by multiplication rather than reactor enlargement", running many identical reactors in parallel. The company is also developing "automated micropropagation through AI-assisted robotic cutting" with an outside robotics firm. Its claims of six-week cycles and 20-fold yields are its own.

What the EIC Project Promised, and What CORDIS Shows

AlkaBurst2.0 promised "a game changing bioreactor for sustainable production of active pharmaceutical ingredients". It delivered the 40-litre reactor, purified material matching reference standards and a "full process book" used "to define the future GMP roadmap". It also reports several pre-clinical collaborations testing Alkion's QS-21 in vaccine programmes, without naming them. Production under GMP, which pharmaceutical customers need, was not reached within the project.

1. New bioreactor generationDelivered40-litre, validated.
2. Pharma-grade QS-21DeliveredEquivalent to references, per CORDIS.
3. GMP productionNot yetFunded by 2025 round.
4. Paying customersNot namedPre-clinical collaborations only.

What Has Happened Since the Award

After the project ended Alkion closed its €4.4 million round and, according to the register, increased its capital in October and December 2025. The team grew to 13 in 2025, from four reported in 2023.

The Money

Alkion files its accounts with a confidentiality declaration, so its revenue is not public. The net result recorded by Pappers was a loss of €202,000 in 2023, a profit of €69,000 in 2024 and a loss of €386,000 in 2025.

Why Europe Should Care

QS-21 comes from the bark of Chilean trees. Alkion's investors present its reactor process as a way of "reinforcing European health sovereignty". The EIC paid most of the development; the GMP plant that would make it real is the next step.

The Verdict

Alkion BioInnovations has not been asked for comment for this article. It is based entirely on company statements, French company data and EU project data, linked throughout.